Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
267 hedge funds and large institutions have $8.95B invested in Sage Therapeutics in 2019 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 132 increasing their positions, 59 reducing their positions, and 35 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 59
90% more capital invested
Capital invested by funds: $4.71B → $8.95B (+$4.24B)
79% more call options, than puts
Call options by funds: $177M | Put options by funds: $98.9M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
57% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 35
8% more funds holding
Funds holding: 248 → 267 (+19)
4.41% more ownership
Funds ownership: 106.12% → 110.53% (+4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$219M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$197M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.7M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$71.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$53.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$48.7M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$27.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.6M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$19M |
SAGE Hedge Fund Activity: Q1 2019 in Review
267 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2019, worth a combined $8.95B — up 90% from $4.71B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new SAGE positions and 35 closed out — a net gain of 20 holders — while 132 added to existing stakes and 59 trimmed.
The largest buyer was Jennison Associates, adding an estimated $219M. The largest seller was Bank of New York Mellon, cutting an estimated $53.4M.
- 267 institutional investors held Sage Therapeutics (SAGE) as of Q1 2019, up from 248 in Q4 2018.
- Funds reported $8.95B of Sage Therapeutics stock for Q1 2019, up 90% quarter-over-quarter.
- 55 funds opened new Sage Therapeutics positions in Q1 2019 and 35 closed out, a net change of +20 holders.
- The largest Sage Therapeutics buyer in Q1 2019 was Jennison Associates, an estimated $219M added.
- The largest Sage Therapeutics seller in Q1 2019 was Bank of New York Mellon, an estimated $53.4M sold.
Based on aggregated 13F filings for Q1 2019.